Tomer Mark, M.D.

Medical Oncology

Publications

Peer Reviewed Articles:

1) Shi H., Djikeng A., Mark T., Wirtz E., Tschudi C., Ullu E. Genetic interference in Trypanosoma

brucei by heritable and inducible double-stranded RNA. RNA. 6(7):1069-76, July 2000.

2) Ruben Niesvizky, Tara Naib, Paul Christos, David Jayabalan, Jessica R Furst, Jessica Jalbrzikowski, Faiza Zafar, Tomer Mark, Richard Lent, Roger Pearse, Scott Ely, John Leonard, Madhu Mazumdar, Selina Chen-Kiang, Morton Coleman. Lenalidomide Induced Myelosuppression is Associated with Renal Dysfunction: Toxicity Evaluation of Treatment Naïve Patients Undergoing Front-Line Lenalidomide and Dexamethasone Therapy.

Br J Haematology. 2007 Sep;138(5):640-3.

3) Niesvizky, R;., Martínez-Baños, D., Jalbrzikowski J., Christos P., Furst J., DeSancho M., Mark T., Pearse R., Mazumdar M., Zafar F., Pekle K., Rambo A., Leonard J., Jayabalan D., Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia and Lymphoma. 2007 Dec;48(12):2330-7.

4) Ruben Niesvizky, David S. Jayabalan, Paul J. Christos, Jessica R. Furst, Tara Naib, Scott Ely, Jessica Jalbrzikowski, Roger N. Pearse, Faiza Zafar, Karen Pekle, Richard Lent, Tomer Mark, Hearn J. Cho, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael Schuster, Susan Mathew, John P. Leonard, Madhu Mazumdar, Selina Chen-Kiang, and Morton Coleman.

BiRD (Biaxin®[clarithromycin]/Revlimid®[lenalidomide]/dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Naïve Symptomatic Multiple Myeloma. Blood. 2007. In press, Epub ahead of print PMID: 17989313

5) Tomer Mark, Ruben Niesvizky. Treatment of multiple myeloma and myelodysplastic syndromes with immunomodulatory derivates. US Oncological Disease. 2008. Accepted for publication.

Abstracts:

1) Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy On Stem Cell Collection In Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Tomer Mark, David Jayabalan, Roger N Pearse, Jessica Stern, Jessica Furst, April Rambo, John Harpel, Tsiporah Shore, Michael Schuster, John P Leonard, Paul J Christos, Morton Coleman, and Ruben Niesvizky. Poster Presentation at the American Society of Hematology Meeting, 2007.

2) Atypical Serum Immunofixation Pattern (ASIP) Development During Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Tomer Mark, David Jayabalan, Roger N Pearse, Y. Lynn Wang, Richard Lent, Paul J Christos, Joong W Lee, Yashpal P Agrawal, Susan Matthews, Scott Ely, Madhu Mazumdar, Ethel Cesarman, April Rambo, John P Leonard, Morton Coleman, Selina Chen-Kiang, and Ruben Niesvizky, MD. Poster Presentation at the American Society of Hematology Meeting, 2007.

3) Stem cell collection prior to autologous stem cell transplantation is improved by cyclophosphamide in lenalidomide-treated patients with multiple myeloma.

Tomer Mark, David Jayabalan, Roger N Pearse, Jessica Stern, Jessica Furst, April Rambo, John Harpel, Tsiporah Shore, Michael Schuster, John P Leonard, Paul J Christos, Morton Coleman, and Ruben Niesvizky. Poster Presentation at the Bone Marrow Transplantation Tandem Meetings. 2008.

Back to topBack To Top